Skip to main content

Advertisement

Table 1 Patients characteristics

From: Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation

Characteristic All patients no. = 40
Median age, years (range) 42.1 (26–76)
Median KPS 80 (60–100)
Histotype:  
   Glioblastoma multiforme 14 (35%)
   Anaplastic astrocytoma 11 (27.5%)
   Anaplastic oligoastrocytoma 7 (17.5%)
   Anaplastic oligodendroglioma 8 (20%)
Prior surgery  
   Biopsy 8 (20%)
   Partial resection 7 (17.5%)
   Total resection 25 (62.5%)
Prior radiotherapy 40 (100%)
Prior lines of chemotherapy  
   1 30 (75%)
   2 10 (25%)
Type of prior chemotherapy  
   TMZ 30 (75%)
   PCV – TMZ 10 (25%)
Second surgery 19 (47.5%)
Median time from diagnosis, months (range) 20 (8–173)
   Glioblastoma multiforme 10 (8–108)
   Anaplastic astrocytoma 28.4 (10–60)
   Anaplastic Oligoastrocytoma 35 (9–173)
   Anaplastic Oligodendroglioma 25 (11–118)
  1. KPS, Karnofsky Performance Status; no, number; PCV, procarbazine-lomustine-vincristine; TMZ, temozolomide